Amendment No. 5 to Schedule 13G for Ernexa Therapeutics Inc.

This filing details an amendment to Schedule 13G for Ernexa Therapeutics Inc. (formerly Eterna Therapeutics, Inc.), reporting changes in beneficial ownership. The reporting persons are Freebird Partners LP, Freebird Investments LLC, and Curtis W. Huff. Freebird Investments LLC acts as the general partner of Freebird Partners LP, and Curtis W. Huff is the sole member of Freebird Investments LLC. This structure implies shared voting and dispositive power among these entities and Mr. Huff regarding the securities held by Freebird Partners LP. The amendment reflects an update following a 1-for-15 reverse stock split of the Issuer's common stock, effective June 10, 2025. It also incorporates changes to beneficial ownership information, including shares held directly and shares issuable upon exercise of pre-funded warrants. The ownership percentage reported is 9.9%, based on an aggregate of 7,899,514 shares of common stock outstanding, which includes both outstanding shares and shares issuable from warrants, subject to a 9.99% ownership blocker limitation on warrant exercise.